RecruitingNot ApplicableNCT06325384
Real World Evaluation of Lifelight®: A Contactless Vital Signs Monitor for Self-monitoring Blood Pressure and Its Comparison to Standard of Care
VISION-Real World Evaluation
Sponsor
Xim Limited
Enrollment
500 participants
Start Date
Feb 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A randomised controlled trial for comparison of real-world feasibility and clinical outcomes of two different methods of home blood pressure monitoring Participants aged 18 years or over with diagnosed and treated hypertension (including via lifestyle interventions) that is not controlled (i.e. in-clinic measurement is 140/90 mmHg or greater) will be recruited from hypertension hospital clinics
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria7
- years or older
- Established diagnosis of hypertension
- Uncontrolled hypertension defined as office blood pressure ≥140/90mmHg.
- Patients who are pharmacologically treated for their hypertension should have been on stable medication for at least 4 weeks.
- Ability to read, write and understand English to complete the study.
- Capacity to give free, valid informed consent.
- A compatible device that supports Lifelight®, as per xim Ltd.'s constantly updating list of compatible devices. If this is not possible, xim Ltd, might provide a similar device for the purpose of the study.
Exclusion Criteria9
- Patients with stage III hypertension with office blood pressure ≥180/120mmHg or it is unsafe to keep them in the study, in the opinion of the investigators.
- Individuals with diagnosed atrial fibrillation.
- Patients with significant arrhythmias such as SVT (Supraventricular tachycardia) or any rhythm that has significant impact on their BP, poor perfusion, pregnancy, pre-eclampsia, deformities or abnormalities which may prevent proper application of a BP cuff, or skin disorders (anaemia, jaundice, rosacea, psoriasis, acute acne, and erythropoietic protoporphyria)
- Participants who are unwilling to undertake self-monitoring or lacking capacity.
- Partners or spouses of individuals already randomised in the trial
- Patients on dialysis or known ESRD (End-stage kidney disease)
- Patients on active cancer treatment
- Terminally ill patients
- Patients who cannot tolerate sitting for up to one hour.
Interventions
DEVICELifelight
Contactless Vital Signs Measurement via RPPG
DEVICEBlood Pressure Cuff
Standard Blood Pressure Cuff Digital
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06325384
Related Trials
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT0605963898 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
NCT052937561 location
Coaching and Navigation by Community Health Workers (CHWs) Through Telehealth for High-risk Hypertension
NCT074614154 locations
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
NCT074820201 location